The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Entecavir Accord entecavir Generic | Accord Healthcare S.L.U. | Hepatitis B, Chronic | 🇪🇺 EU 2017-09-25 | Order → |
| Symtuza darunavir;cobicistat;emtricitabine;tenofovir alafenamide | Janssen-Cilag International | HIV Infections | 🇪🇺 EU 2017-09-21 | Order → |
| Tecentriq atezolizumab | Roche Registration GmbH | Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung; Urologic Neoplasms; Breast Neoplasms; Small Cell Lung Carcinoma | 🇪🇺 EU 2017-09-20 | Order → |
| Bavencio avelumab | Merck Europe B.V. | Neuroendocrine Tumors | 🇪🇺 EU 2017-09-18 | Order → |
| Entecavir Viatris (previously Entecavir Mylan) entecavir Generic | Viatris Limited | Hepatitis B | 🇪🇺 EU 2017-09-18 | Order → |
| Lacosamide Accord lacosamide Generic | Accord Healthcare S.L.U. | Epilepsy | 🇪🇺 EU 2017-09-18 | Order → |
| Rydapt midostaurin Orphan | Novartis Europharm Ltd | Leukemia, Myeloid, Acute; Mastocytosis | 🇪🇺 EU 2017-09-18 | Order → |
| Xermelo telotristat ethyl Orphan | SERB SAS | Carcinoid Tumor; Neuroendocrine Tumors | 🇪🇺 EU 2017-09-17 | Order → |
| Cuprior trientine | Orphalan | Hepatolenticular Degeneration | 🇪🇺 EU 2017-09-05 | Order → |
| Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan efavirenz;emtricitabine;tenofovir disoproxil Generic | Mylan Pharmaceuticals Limited | HIV Infections | 🇪🇺 EU 2017-09-05 | Order → |
| Fotivda tivozanib hydrochloride monohydrate | Recordati Netherlands B.V. | Carcinoma, Renal Cell | 🇪🇺 EU 2017-08-24 | Order → |
| Imraldi adalimumab Biosimilar | Samsung Bioepis NL B.V. | Spondylitis, Ankylosing; Arthritis, Rheumatoid; Uveitis; Colitis, Ulcerative; Psoriasis; Arthritis, Psoriatic; Crohn Disease; Hidradenitis Suppurativa; Arthriti | 🇪🇺 EU 2017-08-24 | Order → |
| Nitisinone MDK (previously Nitisinone MendeliKABS) nitisinone Generic | MendeliKABS Europe Ltd | Tyrosinemias | 🇪🇺 EU 2017-08-24 | Order → |
| Kisqali ribociclib | Novartis Europharm Limited | Breast Neoplasms | 🇪🇺 EU 2017-08-22 | Order → |
| Mavenclad cladribine | Merck Europe B.V. | Multiple Sclerosis | 🇪🇺 EU 2017-08-22 | Order → |
| Maviret glecaprevir;pibrentasvir Accelerated assessment | AbbVie Deutschland GmbH & Co. KG | Hepatitis C, Chronic | 🇪🇺 EU 2017-07-26 | Order → |
| Vosevi sofosbuvir;velpatasvir;voxilaprevi | Gilead Sciences Ireland UC | Hepatitis C, Chronic | 🇪🇺 EU 2017-07-26 | Order → |
| Insulin lispro Sanofi insulin lispro Biosimilar | Sanofi Winthrop Industrie | Diabetes Mellitus | 🇪🇺 EU 2017-07-19 | Order → |
| Veltassa patiromer | Vifor Fresenius Medical Care Renal Pharma France | Hyperkalemia | 🇪🇺 EU 2017-07-19 | Order → |
| Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva efavirenz;emtricitabine;tenofovir disoproxil Generic | Zentiva k.s. | HIV Infections | 🇪🇺 EU 2017-07-17 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.